Member Info for The_Paladin

Most LTIs have maintained or added to their Synairgen investment over the last two years, believing that SNG001's efficacy as a host directed broad spectrum anti viral treatment will eventually be proven through a series of trials.

Unfortunately our belief in a product, underpinned by a myriad of scientific evidence, is taking far longer than expected to being validated. I believe that Synairgen's executives have tried various means to achieve a way forward, but have been unsuccessful thus far.

Their reluctance to communicate with investors has resulted in our current situation. Synairgen is valued in line with its cash reserve. Consequently, the share price will continue to fall, unless the company can communicate something positive about its current strategy.

I resent the comments of contributors who dismiss the views of others by making silly accusations, as was the case with my contribution yesterday. Two attempts were made to deflect my original comment by challenging my position as a Synairgen investor? I see no logical reason for this? It only leads to further comments about the status of the individuals making these accusations.

The forum has been set up to offer investors a means of communicating about their investment. Unfortunately, Synargen's apparent lack of progress makes it difficult to sustain meaningful and relevant communication. My thanks to all who share tangentially relevant scientific insights relating to SNG001. Some are interesting to read, and help to maintain a belief that one day Synairgen's executives will have something positive to communicate.

GLALTIs.

Why would anyone object to selling shares @ 30p, and buying them back again @ 5p per share? I am envious of the smart investors, who managed to do just that. Following TFG's strategy was not so smart and I am poorer today as a result of doing so.

GLALTIs.

No Fruitsnveg, I merely agreed with a single point made both by Axe-Capital, and Manifesto concerning the timing of the long anticipated RNS. Nothing else.

I have agreed with some of your points in the past, and currently agree with TommyD_19 that there is a lot of nonsense being expressed on this forum owing to the dearth of information from the company over five months.

Surely it shouldn’t take in excess of two years to devise a recovery strategy for a moonshot product? Hence my comment about the quality of the company’s leadership team earlier today.

The multiple account nonsense is a diversionary tactic issued by a few “contributors”. This silly response is invariably made in defence of anything inappropriate, but apparently true, being expressed about Synairgen personnel.

Ironically, I have sometimes thought that there are different individuals attending these to these accounts, which makes their accusations so ironic.

Unfortunately, I too believe that Axe -Capital and Manifesto are correct.

The outstanding individuals in this company are the scientists, whose diligence, hard endeavour and brilliance resulted in SNG001.

Sadly, the executives that run the company are mediocre AIM-level directors at best. They are capable of going through the motions, and ticking boxes. They do what is necessary, nothing else. When they were put to the test, they failed miserably, and lacked the humility to acknowledge the fact.

I agree with Fruitsnveg that the company has a potential “moonshot” broad spectrum anti-viral product, which has been sitting on the shelf for two years. When I consider the extravagant expenditure, including board expenses, and executive pay deals and options, over the last two years, it makes me believe that a lot more should have been achieved in that time! Currently, the company is spending the residue of investor capital on P2 trials. Five months since their announcement, the CEO has lacked the basic courtesy of informing us how they are faring! No doubt, he will continue to wait until the last possible opportunity before informing us. Should it be yet another delay, he will confirm the very low opinion that a large number of investors hold as to his credibility.

GLALTIs.

Unfortunately, the “sell on the RNS bounce” narrative doesn’t work for far underwater LTIs. Good luck with that if it works for you.

Many of us, who believed in a successful P3 outcome just over two years ago, and have held and added since then, need a different exit. Personally, I require a significant multibagger to recover my original investment. This can only result from successful P2 outcomes, followed by a JV venture to take the treatment further.

I doubt whether a buyout, as some suggest, is a feasible outcome? Surely if this were a possible scenario, it would have been enacted earlier?

GLALTIs.

My previous comment is still valid, although if the CEO doesn’t issue a statement soon, his credibility with many investors will continue to wane. Two years is more than enough time for any credible company to table funded “concrete” proposals following a serious setback.

Mr. Marsden’s fuzzy rhetoric has prevailed for too long. New potential investors need hard facts and costings upon which to base their decisions.

As for LTIs, we are the long forgotten majority in the eyes of this company. It was our funding that enabled the last P3 trial, and its residue has enabled its well-rewarded executives to remain in situ since then. It is high time for Mr. Marsden to show LTIs more respect.

GLALTIs.

Trinityman.

It was good to read your recent salient points, and I was hopeful of your return as a regular contributor to this forum. Your detailed, well-researched, and thoughtful contributions invariably resonate positively with my own thoughts about this particular investment.

Equally, I was sorry to read about your health issue, and extend my support, and very best wishes as you recover to good health.

Take care, T_P.

BertieBassett,

This was my view also, following the orchestrated sequence that unfolded during the first two months of Q1.

Given the intrinsic value within the company, how long can certain parties continue with the ongoing fiasco that we have been treated to? Their self-rewarding strategy is so transparent, yet they persist with it, and are allowed to get away with it? Surely there won’t be yet another round of the same unsubtle tactics?

My personal approach will be to continue to hold through thick and thin, in anticipation of a worthwhile reward at the end? I seriously thought of selling at 5p+ in anticipation of subterfuge? However, that approach is based on tracking, and gambling on the greed of others. Probably not the best investment strategy, but a perfectly reasonable approach as it turned out in light of the way that long term IQAI investors have been treated!

GLALTIs.

No need to justify that comment Hallowed. It was obvious what you meant, especially for those of us who have been invested for 2 plus years.

Of course it is true that any small MCap company could go under. The only reason for being invested in SYME was due to the fact that it offered potentially high rewards, but at an associated high risk.

It may yet deliver? The fact is that the CEOs confusing comments have misled investors for quite a time doesn’t negate that there may yet be an upside from here?

Those of us who decide to remain invested will just have to wait and see? GLALTIs.

Interesting to note that a thread of five posts, including Trek’s earlier post have been removed? I do not believe that any regular contributor was responsible. Additionally, it isn’t the moderation team, as they rely on posts being reported by multiple readers.

Am I into conspiracy theory territory when I suspect that someone representing a certain individual didn’t enjoy reading some earlier comments? This being the case, a number of subsequent posts, which adopt a similar narrative, will also be removed?

Why is anyone selling middling (24,500000 shares) amount of stock for such a derisory price ( 0.0029p)? What do they hope to gain from this single transaction?

“£300,000 has been raised by the Company through the issue of 20,000,000 new Ordinary Shares (the "Placing Shares")”

It will be interesting whether or not a subsequent TR-1 will inform investors about the ownership of the 20m placing shares? Will the prime suspect choose to keep his suspected acquisition of 9% of the company for a derisory £300K hidden? This could easily be arranged via intermediaries. Nothing would surprise me following this underhand strategy, presumably designed to enrich a small group of well placed investors? No one is fooled by this, and I doubt whether the perpetrators are troubled by naive investors’ opinions’. Moreover, the so - called Broker Option of 4,733,333 shares seems like an arbitrary figure, which will no doubt mostly find itself in the portfolios of a small number of investors?

This entire scenario not only causes retail investors to lose trust in certain manipulative operators, but also in the way that these processes are enacted, apparently without any underpinning from a regulatory body?

I intend to exit from this investment once a break - even point is achieved. I remain hopeful of turning a small profit? However, one cannot be certain how many twists and turns lie ahead on what has proven to be a particularly crooked path?

GLALTIs.

We can endlessly speculate about future possibilities for our drug. Putting first things first, investors need to have some idea about the nature and timelines of the forthcoming trials?

It is only if and when these trials are successfully concluded that we will have some idea of the potential value of our investment ?

I have no disagreement with anybody’s speculation owing to my current dearth of information. However, I still recall my extreme disappointment of two years ago. Before that announcements there was wild speculation about Synairgen investors’ future prosperity. We all know what became of that total misjudgement of our trial outcome.

GLALTIs.

I agree that our drug has significant potential once the company is able to take it beyond successful P2 trialing. It is best to remain positive, until we are updated on Synairgen’s progress in getting these trials underway.

Perhaps, my strategy which closely mirrored that of TFG may yet prove to be fruitful? I intend to remain guardedly optimistic until we receive an update.

In Dr. Connelly’s interview, she presented the state of progress with the clinical trials precisely and clearly, as always. Like all good communicators, she made the facts clear to non-specialist investors like me.

However, was there anything new added? I too, am of the opinion that this was staged for the benefit of investors, who were surprised to learn of a cash raise @ 1.5p per share?

I am suspecting that the latter was arranged to benefit a small number of individuals? 9%+ of a company, with significant growth potential, especially from our current position, for £300K? This doesn’t seem right to me?

It all happened very abruptly from a position when the market seemed to be responding appropriately to the news regularly conveyed to investors. Most of us, I am sure, expected the share price to steadily rise from the 5p point at the start of January? The massive sell off, abruptly followed by a cash raise at 30% of the early year share price has the hallmarks of a planned manoeuvre?

I am a mere observer here, and am not suggesting any impropriety. At best, I am disappointed with the sell off by the CEOs family company? They were within their rights, but their actions have so far been to the detriment of IQAI investors. We shall just have to wait and see what develops? I shall continue to hold, but have lost trust in the CEOs intentions for the company. He will need to do more than arrange a positive Proactive Investors presentation to recapture that trust.

Manifesto.

Your point about Synairgen's funding issues is well made and accepted, by me at least. Synairgen's financial position is tight. I believe that in the following pre-trial months, they will take it to the wire. However, without access to Joseph Colliver's laptop, I have no way of knowing that. For the time being, I have little choice but to accept what the company last relayed about their financials on September 21. It is virtually impossible to extrapolate from that point, as we have not yet received an update.

It is probably unwise not to obsess too much about any Synairgen-related issue. I offer myself as a case in point. Last night, I watched an enjoyable Zack Snyder film. Sadly part of the film's soundtrack made me think of Synairgen's recent lack of communication with investors. i intend to do all I can to guard against this happening in future!

https://www.youtube.com/watch?v=IfIyWxaPLuA

“Still can't fathom why they let it drift down to these low levels and announced the placing? What is more significant the 20m additional shares, or the 300k?”

It means that 9%+ of the company will be purchased for 30% of the share price at the turn of the year.

Had the same cash raise been activated at the start of the year, it would have required 6m shares ( < 3% of the company) to raise the £300K that the company apparently needs to continue its trialling.

It was never an option for the BOD to stabilise the share price at the higher level. The plan was for certain interested parties to acquire a significant share of a promising company for a paltry sum IMHO. The invitation for shareholders to participate in a further £100K share rise shouldn’t tempt anyone. We can currently buy stock at c. 1.5p per share if we wish to do so.

I take consolation in the fact that the only important consideration is that my current holding will hopefully be sold at my target price sometime in the future. It would have helped to have an investor friendly BOD in place to enable my target to be achieved sooner rather than later.

I wish all LTIs a great weekend,

I agree. I value Doc.Daneeka’s contributions highly. They are carefully researched, and the facts are expressed in his own words, not merely cut and paste from specialist journals.

The latter are difficult for a layman like myself to comprehend without considerable effort to decipher the jargon. This is why I value individuals’ contributions in which an effort has been made to express their thoughts in language that is readily accessible to others.

Understanding the science underpinning this investment is important, but not every investor wants to read about it in great detail.

I value all contributors’ efforts on this forum. To disparage other individuals’ opinions merely to score points is inappropriate in my view.

A precisely targeted trial cohort, partly identified by a state of the art testing regime, as yet, unspecified by the company? The use of AI technology to accelerate trial progression, including formative and summative data analysis presumably?

This is cutting edge technology requiring substantial investment IMHO, even for small P2 trials. Our capital reserve is dwindling, in no small measure due to the staffing structure at Synairgen.

Today, I retain a measure of optimism for a favourable outcome. Surely, given the two years taken to analyse all available company data, and to plan a future strategy, investors have good reasons to be optimistic?

However, our cash position is fragile to say the least, and the potential nine month delay (from the last company announcement) to get a trial underway only adds to investors concerns.

The principle of a cash raise with it’s associated dilution has been summarily dismissed on this forum. I have no good reason to support the latter principle. However, with no reassuring detailed information from the company for five months, it is an issue of concern for investors.

In my unfortunate experiences as an investor, I have no good reason to trust statements of future intent issued by any company. GLALTIs.